University of Nottingham CiC#7: accelerating translation of novel, early-stage interdisciplinary, biomedical research
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
People |
ORCID iD |
Publications
Al-Beltagi S
(2021)
Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin.
in Virulence
Allen CM
(2021)
Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.
in Annals of neurology
Blake H
(2020)
Perceptions and Experiences of the University of Nottingham Pilot SARS-CoV-2 Asymptomatic Testing Service: A Mixed-Methods Study
in International Journal of Environmental Research and Public Health
Corden C
(2023)
Autofluorescence-Raman Spectroscopy for Ex Vivo Mapping Colorectal Liver Metastases and Liver Tissue.
in The Journal of surgical research
Corden C
(2021)
Sub-Surface Molecular Analysis and Imaging in Turbid Media Using Time-Gated Raman Spectral Multiplexing.
in Applied spectroscopy
Corden C
(2021)
Time-gated Raman spectroscopy for biomedical application under ambient or strong background light conditions
in Journal of Physics D: Applied Physics
Goulding LV
(2020)
Thapsigargin at Non-Cytotoxic Levels Induces a Potent Host Antiviral Response that Blocks Influenza A Virus Replication.
in Viruses
Ting DSJ
(2020)
Strategies in Translating the Therapeutic Potentials of Host Defense Peptides.
in Frontiers in immunology
| Description | Coordinating COVID-19 Asymptomatic Testing Programmes In University Settings: Providing Insight On Acquired Immunity Across The Student Population |
| Amount | £7,200,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 03/2021 |
| Description | Development of novel broad-spectrum antiviral compounds for use in animals and humans |
| Amount | £764,392 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2024 |
| Description | MICRA grant to Prof. Ilyas |
| Amount | £15,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2020 |
| End | 06/2021 |
| Description | MICRA grant to Prof. Notingher |
| Amount | £7,400 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2020 |
| End | 06/2021 |
| Description | Preclinical Safety And Efficacy Of Cathelicidin-derived Peptide And Vancomycin Combination For Pseudomonas Keratitis |
| Amount | £76,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 01/2022 |
| Description | Research Collaborative - DEMISTIFI Multi Morbidity: DEfining MechanIsms Shared across mulTI-organ FIbrotic disease to prevent the development of long term multi-morbidity |
| Amount | £3,335,901 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2021 |
| End | 06/2025 |
| Description | TOPICAL |
| Amount | £99,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 01/2022 |
| Description | Preparing for first in man trials of 3D printed solid dosage forms |
| Organisation | Added Scientific Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Staff, research expertise and know-how |
| Collaborator Contribution | Facilities and expertise to perform work in GMP environment |
| Impact | No outcomes as of yet, project still in progress. Project is multi-disciplinary, bringing together engineering and pharmacy teams |
| Start Year | 2019 |
| Description | Preparing for first in man trials of 3D printed solid dosage forms |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Staff, research expertise and know-how |
| Collaborator Contribution | Facilities and expertise to perform work in GMP environment |
| Impact | No outcomes as of yet, project still in progress. Project is multi-disciplinary, bringing together engineering and pharmacy teams |
| Start Year | 2019 |
| Description | Preparing for first in man trials of 3D printed solid dosage forms |
| Organisation | Quotient Clinical Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Staff, research expertise and know-how |
| Collaborator Contribution | Facilities and expertise to perform work in GMP environment |
| Impact | No outcomes as of yet, project still in progress. Project is multi-disciplinary, bringing together engineering and pharmacy teams |
| Start Year | 2019 |
| Description | Protein quality reference score for assessing digestibility |
| Organisation | Arla Foods |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of research labs, staff, patients and expertise from academics |
| Collaborator Contribution | Provision of labelled proteins and expertise |
| Impact | None yet |
| Start Year | 2019 |
| Title | ANTIVIRAL COMPOUNDS AND METHODS |
| Description | The invention provides an agent for the treatment or prevention of viral infection in a subject. The agent is preferably a compound of Formula (I) or (la) wherein R1-R4, A and B are as defined herein. Also provided are pharmaceutical compositions and combinations comprising such agents. |
| IP Reference | WO2021069891 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | None as yet |
| Title | SOCE FACILITATORS FOR USE IN TREATING OR PREVENTING VIRAL INFECTIONS |
| Description | Published online |
| IP Reference | GB2020/052479 |
| Protection | Patent application published |
| Year Protection Granted | |
| Licensed | No |
| Impact | Impact exploration ongoing |